Septerna, Inc.
Septerna is a clinical-stage biotechnology company based in South San Francisco, California. It uses its proprietary Native Complex Platform® to discover and develop oral small-molecule drugs that target G protein-coupled receptors (GPCRs). The platform recreates GPCR structures and functions outside cells, enabling the company to identify and optimize potential drug candidates. Septerna’s wholly owned pipeline focuses initially on endocrinology, immunology and inflammation, and metabolic diseases. Its programs include oral small-molecule candidates targeting PTH1R for hypoparathyroidism, MRGPRX2 for chronic spontaneous urticaria and other mast cell-driven diseases, and TSHR for Graves’ disease and thyroid eye disease. Septerna is advancing candidates through clinical development; its stated business is drug discovery and development, rather than the sale of marketed products.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Wells Fargo kept its Overweight rating on Septerna but increased its price target to $61 from $50, suggesting a 39.6% upside from the Nov 3 close of $43.70.
Septerna, Inc. (SEPN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Septerna Announces Selection of SEP-204 as Development Candidate for Graves’ Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, th
Septerna (SEPN) disclosed that its CMO, Rajiv Patni, received 275,000 stock options on September 8, 2026, with an exercise price of $37.37 per share. The options expire on September 7, 2036, with 25% vesting on August 24, 2027, and the remainder in monthly installments over three years, contingent on his continued service.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning SEPN (Septerna, Inc.). Coverage has skewed bullish: 1 bullish, 0 neutral, and 0 bearish.
Recent SEPN coverage spans financial news, insider activity and technology.
In the last 30 days, SEPN insiders filed 2 SEC Form 4 transactions — no purchases and 2 sales ($150K). The most active reporter was Bhatt Elizabeth, President and COO, with 2 filings. 100% of those filings were made under pre-arranged Rule 10b5-1 plans.
Wells Fargo kept its Overweight rating on Septerna but increased its price target to $61 from $50, suggesting a 39.6% upside from the Nov 3 close of $43.70.
Positive preclinical results suggest strong clinical potential, likely driving short‑term buying interest.
Small insider option grant with modest potential dilution; limited immediate price impact.
Septerna, a biotech company, granted stock awards to new employees under Nasdaq's Rule 5635(c)(4). The awards are part of an inducement plan to attract talent. According to the company, the grants are intended to align employees' interests with shareholders' long-term success.
No immediate price impact expected as the filing reports zero holdings.
AlphAI scores every news story that mentions SEPN with an AI model for sentiment and relevance, and aggregates insider trades from Septerna, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo kept its Overweight rating on Septerna but increased its price target to $61 from $50, suggesting a 39.6% upside from the Nov 3 close of $43.70.
1 min readSepterna, Inc. (SEPN) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Septerna Announces Selection of SEP-204 as Development Candidate for Graves’ Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting Potent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, th
2 min readSepterna (SEPN) disclosed that its CMO, Rajiv Patni, received 275,000 stock options on September 8, 2026, with an exercise price of $37.37 per share. The options expire on September 7, 2036, with 25% vesting on August 24, 2027, and the remainder in monthly installments over three years, contingent on his continued service.
1 min readSepterna, a biotech company, granted stock awards to new employees under Nasdaq's Rule 5635(c)(4). The awards are part of an inducement plan to attract talent. According to the company, the grants are intended to align employees' interests with shareholders' long-term success.
1 min readSepterna's (SEPN) new Chief Medical Officer, Rajiv Patni, filed an initial ownership report showing no share holdings or insider trades. The filing includes a Power of Attorney authorizing the submission.
1 min readSepterna (SEPN) appointed Rajiv Patni, M.D., as Chief Medical Officer, bringing 25+ years of biopharmaceutical experience. Investors may view this as positive for advancing its pipeline and meeting clinical milestones, despite current losses. The company's valuation is tied to its GPCR-focused platform and early clinical assets, with key catalysts being SEP-631 and SEP-479 trials, and a Novo Nordisk collaboration. Dr. Patni's regulatory expertise could improve trial and regulatory execution, but
2 min readSepterna Inc. (SEPN) appointed Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni has over 20 years of experience in clinical development and regulatory affairs. The company aims to advance its GPCR-targeted medicines into clinical trials. SEPN's stock closed at $40.52, up 1.30%, and is currently trading at $40.44 in pre-market.
1 min readInvesting.com reported major US insider trades disclosed Friday. Buys: PAL director Rohit Lal bought $272.5k; OTLK director/10% owner Ghiath Sukhtian bought about 2.5M shares and warrants for ~$2.5M; CLPR director Sam Levinson bought ~$488.8k; OPFI CEO Todd Schwartz bought ~$144k; OPEN CEO Kasra Nejatian bought ~$100k. Sells: CRWV 10% owner Magnetar sold ~$231.6M then ~$213.8M; ANET CEO Ullal trust sales ~$119.3M; SEPN RA Capital sold $63.45M; KRYS director Rossi sold ~$8.23M.
7 min readThird Rock Ventures V, L.P. sold 147,200 shares of Septerna, Inc. (SEPN) at an average of $50.27 ($50.27–$51.08, $7.40M total) across 2 trades on 2026-08-12 under a Rule 10b5-1 trading plan. Filed jointly with Third Rock Ventures GP V, LP (10% owner), TRV GP V, LLC (10% owner), Third Rock Ventures VI, L.P. (10% owner), Third Rock Ventures GP VI, L.P. (10% owner) and TRV GP VI, LLC (10% owner).
2 min readRA CAPITAL MANAGEMENT, L.P. sold 1,493,000 indirectly-held shares of Septerna, Inc. (SEPN) at $42.50 ($63.45M total) across 2 trades on 2026-08-12. Filed jointly with RA Capital Healthcare Fund LP (Director), RA Capital Nexus Fund III, L.P. (Director), Kolchinsky Peter (Director) and Shah Rajeev M. (Director).
2 min read
